Abstract 1588P
Background
Esophagectomy is a high-risk surgical procedure with significant postoperative morbidity and mortality. Anastomotic leakage is still one of the most serious complications after anterior resection for esophageal carcinoma. This study aimed to analyze the risk factors after minimally invasive cervical anastomosis of esophageal cancer and postoperative mortality.
Methods
This was a retrospective study of 312 minimally invasive cervical anastomosis of esophageal cancer in a single institute between 2013 and 2016. The anastomotic level and perioperative confounding factors were analyzed by univariate and multivariate logistic regression to identify potential risk factors for postoperative leakage.
Results
Total 312 patients were evaluated. Overall leak rate was 10.6%. In-hospital or 30-day mortality was 0%. Only 3 patients received intensive care unit due to postoperative complications and mean hospital stay was 14.22 (±7.70) days. Univariate analysis showed that the following variables were related to the incidence of anastomotic leakage: neoadjuvant chemotherapy before operation (p=0.007); body mass index (BMI) (p=0.000); diabetes (p=0.001); operation time (p=0.006). Multivariable analysis identified diabetes [P = 0.032, odds ratio (OR) 2.637, 95% confidence interval (CI): 1.087-6.393], BMI [P = 0.003, odds ratio (OR) 1.223, 95% confidence interval (CI): 1.070-1.399] and operation time [P = 0.033, odds ratio (OR) 1.012, 95% confidence interval (CI): 1.001-1.024] as the risk factors of anastomotic leakage.
Conclusions
Diabetes, operation time and BMI are independent prognostic factors for cervical anastomotic leakage of minimally invasive esophageal cancer. Cervical anastomotic leakage will not affect the short-term survival of the patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Lu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22